Eli Lilly & Co. (LLY) Granted FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for Preventive Treatment of Episodic Cluster Headache in Adults
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
